Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-Cell or B-Cell Precursor Acute Lymphoblastic Leukaemia or T-Cell Non- Hodgkin's Lymphoma.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Approved-not yet active
2 to 18
Pharmaceutical / Industry
2008-00221942
BCX1777-108, NCT00742495
2.
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
BCX1777-203
NCT00501735
Last Modified:
5/22/2008
 
First Published:
8/14/2007
3.
Phase II Study of Forodesine Hydrochloride in Patients With Refractory or Recurrent Cutaneous T-Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 and over
Pharmaceutical / Industry
BIOCRYST-BCX1777-203
BCX1777-203, NCT00501735
4.
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
BCX1777-210
NCT00640523
5.
Trial of Forodesine in Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
2007-000256-14
BCX1777-110, NCT00646165
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute